A red-light-activated sulfonamide porphycene for highly efficient photodynamic therapy against hypoxic tumor

Yuzhi Wang,Zhaohai Pan,Xiao-Lan Cheng,Kai Zhang,Xin Zhang,Yao Qin,Jiaojiao Fan,Ting Yan,Tao Han,Kwok Keung Shiu,Sam Chun-Kit Hau,Nai-Ki Mak,Daniel W J Kwong,Xiaona Liu,Minjing Li,Guowei Deng,Qiusheng Zheng,Jun Lu,Defang Li,Daniel W.J. Kwong
DOI: https://doi.org/10.1016/j.ejmech.2020.112867
IF: 7.088
2021-01-01
European Journal of Medicinal Chemistry
Abstract:<p>Photodynamic therapy (PDT) is an emerging alternative cancer treatment modality that utilizes photo-sensitivity to cause cell death upon photo-irradiation. However, PDT efficiency has been hampered by tumor hypoxia, blue-shifted excitation wavelengths, and the high dark toxicity of photo-sensitizers. We designed and synthesized two novel porphycene-based photosensitizers (TBPoS-OH and TBPoS-2OH) with potent photo-cytotoxicity and a LD<sub>50</sub> in the nM range under both normoxic and hypoxic conditions in a variety of cell types after photo-irradiation (λ = 640 ± 15 nm). Further studies showed fast-cellular uptake for TBPoS-OH that localized lysosomes and subsequently induced cell apoptosis via the lysosomal-mitochondrial pathway. Moreover, TBPoS-OH significantly reduced tumor growth in two xenografted mouse models bearing melanoma A375 and B16 cells. Finally, TBPoS-OH exhibited no obvious immunogenicity and toxicity to blood cells and major organs in mice. These data demonstrated that these two porphycene-based photosensitizers, especially TBPoS-OH, could be developed as a potential PDT modality.</p>
chemistry, medicinal
What problem does this paper attempt to address?